Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 5/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19691931 | 1.00 | TSHR (0.43) | TSHRCA12CA14CA2CA1 | |
| SCHEMBL16660376 | 0.89 | CYP2D6 (0.37) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL15984252 | 0.89 | CYP2D6 (0.37) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL2616309 | 0.85 | CA12 (0.39) | TSHRCA12CA14CA2CA1 | |
| SCHEMBL265551 | 0.82 | TSHR (0.52) | TSHRCA12CA14CA2CA1 | |
| SCHEMBL16300949 | 0.82 | TSHR (0.52) | TSHRCA12CA14CA2CA1 | |
| SCHEMBL10010442 | 0.82 | TSHR (0.36) | TSHRCA12CA14SLC1A1CA7 | |
| SCHEMBL9668938 | 0.81 | TSHR (0.43) | TSHRCA12CA14CA2CA1 | |
| SCHEMBL764174 | 0.81 | CYP1A2 (0.54) | TSHRSLC1A1CYP2D6MEN1KMT2A | |
| SCHEMBL14275181 | 0.81 | CYP2D6 (0.40) | TSHRCA12CA14CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275727-A1 | Peptide turn mimetics | MIMETICA PTY LIMITED (AU) | 2009-11-05 | — | — | US | disclosed |
| US-20090275727-A1 | Peptide turn mimetics | MIMETICA PTY LIMITED (AU) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275727-A1 | Peptide turn mimetics | IAPP, GLP1R, VIP | TSHR 382/4885CA12 2437/4885CA14 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.